Do you have $10,000 to put into the share market and a penchant for ASX growth shares?
If you do, then it could be worth considering the three named in this article that brokers rate as buys. Here's why they could be top picks:
Image source: Getty Images
Breville Group Ltd (ASX: BRG)
The first ASX growth share to consider is Breville Group. It sells kitchen appliances, which is a category that many investors assume is mature. But Breville's edge lies in how it treats appliances as premium, design-led products rather than commodities.
The company has spent years building brand loyalty in key global markets, particularly North America and Europe. Once consumers buy into the Breville ecosystem, repeat purchases and word-of-mouth do much of the heavy lifting. That brand-led approach allows the company to command higher prices and protect margins.
In addition, Breville has built a very strong position in the at-home coffee market, which continues to grow at a strong rate. Combined with the rest of the business, Breville could be well-placed for growth over the next decade and beyond.
Citi currently has a buy rating and $36.03 price target on Breville's shares.
NextDC Ltd (ASX: NXT)
Another ASX growth share to consider is NextDC. It sits behind the scenes of the digital economy. Its data centres provide the physical infrastructure that cloud platforms, enterprises, and governments rely on to store and move data securely.
What makes NextDC interesting from a growth perspective is that demand does not arrive evenly. Large contracts tend to come in waves as customers scale up capacity or enter new regions. That can make short-term results look uneven, even while the long-term trajectory remains intact.
As data usage, cloud adoption, and AI workloads continue to grow, the need for secure, well-located data centres is unlikely to fade. NextDC's expanding footprint positions it to benefit as customers' infrastructure requirements become larger and more complex.
Macquarie is bullish on this one and has an outperform rating and $22.30 price target on its shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
A final ASX growth share to look at is Telix Pharmaceuticals. It develops radiopharmaceuticals used in cancer diagnosis and treatment, combining biotechnology with specialised manufacturing and distribution.
What sets Telix apart is that it is transitioning from a development-stage business to a commercial one. As products move from approval into wider clinical use, revenue can scale quickly without the need to reinvent the underlying platform each time.
This creates a growth profile that is tied more to clinical adoption and market penetration than traditional economic cycles. For investors, that introduces volatility, but it also offers exposure to a part of healthcare where innovation can translate directly into earnings growth.
Bell Potter has a buy rating and $23.00 price target on its shares.
